Sequenom settles shareholder suit
This article was originally published in The Gray Sheet
Executive Summary
Firm announces Jan. 15 it will pay $14 million to resolve a class action shareholder suit related to employee mishandling of its SEQureDX Down syndrome test data. Subject to final approval by the U.S. District Court for the Southern District of California, the firm will also issue to the class members and their attorneys 9.95% of its common stock outstanding. Former Sequenom CEO Harry Stylli, CFO Paul Hawran and Senior VP-Research and Development Elizabeth Dragon also have entered into the settlement. Sequenom fired Stylli and Dragon, and Hawran resigned, after an independent investigation revealed the firm failed to put in place adequate protocols and controls for the conduct of studies in the Down syndrome test program, leading to errors in data and inadequately substantiated claims (1"The Gray Sheet" Oct. 5, 2009)
You may also be interested in...
Sequenom Addresses Problems With Tainted Data; CEO Fired
Sequenom will rely on independent third-party validation of all future tests after an investigation into SEQureDX Down syndrome test R&D data revealed mishandling by employees
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.